Table 3 Characteristics of hospitalized and non-hospitalized antidepressant initiators with PD
From: Recent hospitalization and risk of antidepressant initiation in people with Parkinson’s disease
Characteristic | Hospitalized (n = 2653) | Non-hospitalized (n = 2839) | P value |
|---|---|---|---|
Age at index date a, mean (95% CI) | 73.2 (72.8–73.5) | 73.9 (73.5–74.2) | 0.007 |
Time since PD diagnosis, median (IQR) | 3.0 (1.2–5.6) | 2.7 (1.1–5.4) | 0.006 |
Sex, n (%) | 0.18 | ||
Women | 1363 (51.4) | 1510 (53.2) | |
Men | 1290 (48.6) | 1329 (46.8) | |
Comorbidities, n (%) | |||
Cardiovascular diseases | 1118 (42.1) | 1238 (43.6) | 0.27 |
Asthma/COPD | 234 (8.8) | 208 (7.3) | 0.04 |
Diabetes | 309 (11.7) | 301 (10.6) | 0.22 |
PD medication use, n (%) | |||
Any medication for PD | 2511 (94.7) | 2691 (94.8) | 0.82 |
Dopaminergic medication for PD | 2502 (94.3) | 2676 (94.3) | 0.94 |
Dopa and dopa derivatives | 2191 (82.6) | 2345 (82.6) | 0.99 |
Dopamine agonists | 1205 (45.4) | 1,09 (38.7) | < 0.001 |
Monoamine oxidase B inhibitors | 930 (35.1) | 1031 (36.3) | 0.33 |
Other dopaminergic agents | 142 (5.4) | 148 (5.2) | 0.82 |
Other medication use, n (%) | |||
Opioids | 486 (18.3) | 374 (13.2) | < 0.001 |
Antipsychotics | 286 (10.8) | 285 (10.0) | 0.37 |
Benzodiazepines and related drugs | 839 (31.6) | 992 (34.9) | 0.009 |
Acetylcholinesterase inhibitors (AChEI) | 151 (5.7) | 238 (8.4) | < 0.001 |
Memantine | 23 (0.9) | 39 (1.4) | 0.08 |
AChEI/memantine | 158 (6.0) | 248 (8.7) | < 0.001 |
Antidepressant initiation, n (%) | |||
Selective serotonin reuptake inhibitor | 1266 (47.7) | 1374 (48.4) | 0.62 |
Mirtazapine | 996 (37.5) | 964 (34.0) | 0.006 |
Serotonin and norepinephrine reuptake inhibitor (SNRI) | 157 (5.9) | 130 (4.6) | 0.026 |
Tricyclic antidepressant (TCA) | 155 (5.8) | 233 (8.2) | 0.001 |
Other b | 98 (3.7) | 147 (5.2) | 0.008 |
Initiated 2 antidepressants | 19 (0.7) | 9 (0.3) | |